» Articles » PMID: 36928741

Genomic Profiling of the Craniofacial Ossifying Fibroma by Next-Generation Sequencing

Overview
Specialties Oncology
Pathology
Date 2023 Mar 17
PMID 36928741
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ossifying fibroma (OF) of the craniofacial skeleton is a fibro-osseous lesion characterized by various patterns of bone formation in a cellular fibroblastic stroma. The molecular landscape of OF remains mostly unknown. There are a few known pathogenic abnormalities in OF, including HRPT2 mutations in conventional OF and SATB2 translocations in juvenile psammomatoid OF. On the other hand, conflicting reports exist regarding MDM2 gene amplification and chromosomal copy number alterations (CNA) in OF.

Methods: Surgically removed biopsies and curettage specimens from OF patients were obtained. Clinical, radiographic, and pathologic features of tumors were reviewed. Genomic DNA was extracted from formalin-fixed, paraffin-embedded blocks of tumor tissue. Capture-based DNA next-generation sequencing targeting the coding regions 529 cancer genes and select introns was performed.

Results: We identified 17 OF cases from 8 male and 8 female patients with mean age of 22 years (range 1-58 years). Nine case occurred in the gnathic bones and 8 in the extragnathic craniofacial bones. These cases included 3 juvenile psammomatoid OF, 6 conventional OF and 8 juvenile trabecular OF. Large-scale CNAs were present in 6 of 17 cases. Seven cases (41%) had focal amplifications including FOSB (n = 2, 11%), FOS (n = 4, 23%), COL1A1 (n = 4, 23%) and TBX3 (n = 5, 29%). Three cases (17%) had pathogenic CDC73 mutations. No cases showed focal MDM2 amplification.

Conclusions: Here, we provided a comprehensive molecular characterization of OF that reveals a heterogeneous genetic profile with occasional large-scale CNAs (n = 6, 35%). FOS, FOSB, and TBX3 genes that regulate AP-1 transcriptional complex are frequently altered in OF (n = 7, 41%), chiefly in juvenile trabecular OF. These genes encode transcription factors that act as downstream effectors of the MAP kinase signaling pathway. MDM2 amplification is an exceedingly rare event in OF, if present at all, so identification of this event should continue to raise concern for low-grade gnathic osteosarcoma. In summary, our findings suggest that OF represents a heterogeneous group of tumors at the genetic level but dysregulation of the AP-1 pathway may play a role in pathogenesis of juvenile trabecular OF.

Citing Articles

From Genomic Exploration to Personalized Treatment: Next-Generation Sequencing in Oncology.

Vashisht V, Vashisht A, Mondal A, Woodall J, Kolhe R Curr Issues Mol Biol. 2024; 46(11):12527-12549.

PMID: 39590338 PMC: 11592618. DOI: 10.3390/cimb46110744.


Comprehensive analysis of the clinical significance and molecular mechanism of T-box transcription factor 3 in osteosarcoma.

Man Y, Xu H, Chen P, Sun Y, He M J Cancer. 2024; 15(12):4007-4019.

PMID: 38911382 PMC: 11190752. DOI: 10.7150/jca.96168.


Craniofacial disorders and dysplasias: Molecular, clinical, and management perspectives.

Akintoye S, Adisa A, Okwuosa C, Mupparapu M Bone Rep. 2024; 20:101747.

PMID: 38566929 PMC: 10985038. DOI: 10.1016/j.bonr.2024.101747.


Historical Notes on Ossifying Fibroma of the Mandible.

Ide F, Sakamoto S, Nishimura M, Miyazaki Y, Kikuchi K Head Neck Pathol. 2023; 17(4):1021-1025.

PMID: 37943466 PMC: 10739633. DOI: 10.1007/s12105-023-01599-x.


Cemento-Osseous Dysplasia of the Jaw: Demographic and Clinical Analysis of 191 New Cases.

DeColibus K, Shahrabi-Farahani S, Brar A, Rasner S, Aguirre S, Owosho A Dent J (Basel). 2023; 11(5).

PMID: 37232789 PMC: 10217321. DOI: 10.3390/dj11050138.

References
1.
Ghosh T, PACKHAM E, Bonser A, Robinson T, Cross S, Brook J . Characterization of the TBX5 binding site and analysis of mutations that cause Holt-Oram syndrome. Hum Mol Genet. 2001; 10(18):1983-94. DOI: 10.1093/hmg/10.18.1983. View

2.
Candeliere G, Glorieux F, Prudhomme J, St-Arnaud R . Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med. 1995; 332(23):1546-51. DOI: 10.1056/NEJM199506083322304. View

3.
Walther C, Tayebwa J, Lilljebjorn H, Magnusson L, Nilsson J, Vult von Steyern F . A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2013; 232(5):534-40. DOI: 10.1002/path.4322. View

4.
Amary F, Markert E, Berisha F, Ye H, Gerrand C, Cool P . FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool. Am J Surg Pathol. 2019; 43(12):1661-1667. DOI: 10.1097/PAS.0000000000001355. View

5.
Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K . RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416(6882):744-9. DOI: 10.1038/416744a. View